Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Sickle Cell Disease (HbSS, HbSC, HbSβ⁰-thalassemia, or HbSβ⁺-thalassemia)~* If receiving hydroxyurea or erythropoietin, treatment must have been prescribed for at least 6 months, with the dose stable for at least 3 months~* Between 2 and 10 sickle cell-related pain crises in the past 12 months~Key Exclusion Criteria:~* On a chronic transfusion program or planning on exchange transfusion during the study~* Hemoglobin \<4.0 g/dL~* Planned initiation, termination, or dose alteration of hydroxyurea during the study~* Receiving chronic anticoagulation therapy (e.g. warfarin, heparin) other than aspirin

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- High-dose SelG1 (Selg1 5.0 mg/kg) (Type: EXPERIMENTAL): IV Infusion, once every 4 weeks through Week 50
- Low-dose SelG1 (Selg1 2.5 mg/kg) (Type: EXPERIMENTAL): IV Infusion, once every 4 weeks through Week 50
- Placebo (Type: PLACEBO_COMPARATOR): IV Infusion, once every 4 weeks through Week 50

Based on this trial design, predict the completion outcome and termination type (if applicable).